Sirtuin / NAD⁺ axis: NAD⁺ salvage, sirtuin family, and longevity peptides

Detailed explanation

Nicotinamide adenine dinucleotide (NAD⁺) is a central cellular coenzyme required for hundreds of enzymatic reactions including glycolysis, oxidative phosphorylation, fatty-acid oxidation, and the tricarboxylic acid cycle. Beyond its metabolic-coenzyme role, NAD⁺ is a substrate for three families of enzymes with major longevity implications: the sirtuins (NAD⁺-dependent protein deacylases), the PARPs (poly-ADP-ribose polymerases, DNA-damage response), and the CD38/CD157 cyclic-ADP-ribose synthases. Age-related decline in cellular NAD⁺ levels has been documented across multiple tissues and model organisms, and NAD⁺ elevation through precursor supplementation (nicotinamide riboside, nicotinamide mononucleotide) or salvage-pathway enhancement has been proposed as a longevity intervention. The sirtuin family comprises seven mammalian members (SIRT1-SIRT7) with differing subcellular localisations, substrate specificities, and physiological functions. SIRT1 is predominantly nuclear-cytoplasmic and deacetylates transcription factors including p53, FOXO1/3/4, PGC-1α, and NF-κB — regulating stress response, mitochondrial biogenesis, and inflammation. SIRT2 is cytoplasmic and deacetylates tubulin and other substrates. SIRT3, SIRT4, and SIRT5 are mitochondrial with roles in mitochondrial metabolism, ROS management, and mitochondrial acetyl-CoA metabolism. SIRT6 is nuclear-chromatin-associated with roles in DNA repair, telomere maintenance, and glucose metabolism regulation; SIRT6 has emerged as one of the most-validated longevity sirtuins with transgenic overexpression extending lifespan in mice. SIRT7 is nucleolar with roles in ribosomal-DNA transcription and RNA polymerase I regulation. Sirtuin activity is critically dependent on NAD⁺ availability — the deacylation reaction consumes one NAD⁺ per substrate deacylated. Cellular NAD⁺ decline with age therefore progressively limits sirtuin activity, and NAD⁺-elevating interventions activate sirtuins as a downstream consequence. This mechanistic linkage places the NAD⁺ salvage pathway at the centre of sirtuin-based longevity pharmacology. The NAD⁺ salvage pathway proceeds through the rate-limiting enzyme nicotinamide phosphoribosyltransferase (NAMPT), which converts nicotinamide (a NAD⁺-hydrolysis by-product) plus PRPP into nicotinamide mononucleotide (NMN). NMN is then converted by NMNAT enzymes to NAD⁺, completing the salvage cycle. NAMPT is expressed intracellularly (iNAMPT) and secreted extracellularly (eNAMPT/visfatin) with tissue-specific pattern. NAMPT activity declines with age in most tissues and NAMPT-transgenic mice show elevated NAD⁺ and improved metabolic and longevity phenotypes. A critical regulator of NAD⁺ availability is nicotinamide N-methyltransferase (NNMT), which methylates nicotinamide to N1-methylnicotinamide (MNA), sequestering nicotinamide from the NAD⁺ salvage pathway. NNMT overexpression has been documented in obesity, type-2 diabetes, and various cancers; NNMT knockout produces increased NAD⁺, improved metabolic health, and resistance to diet-induced obesity in mouse models. NNMT inhibition has therefore emerged as a validated pharmacological strategy for NAD⁺ elevation and downstream sirtuin activation. Peptide and small-molecule research on this axis includes multiple approaches. MOTS-c and humanin (mitochondrial-derived peptides) engage AMPK-mTOR-mitochondrial pathways with substantial overlap onto sirtuin biology through PGC-1α activation and mitochondrial-biogenesis effects. Epitalon (Epithalon, Ala-Glu-Asp-Gly) has been reported to affect telomerase activity, pineal melatonin regulation, and general longevity phenotype in aged mice — the mechanistic overlap with sirtuin biology involves shared telomere-maintenance and DNA-repair contexts. 5-Amino-1MQ (5-Amino-1-methylquinolinium) is a small-molecule NNMT inhibitor with pharmacology positioning it in the NAD⁺-elevation and sirtuin-activation space — commonly considered alongside peptide MDPs in longevity-research contexts even though 5-Amino-1MQ is not itself a peptide. Standard research assays for sirtuin-NAD⁺ pharmacology include LC-MS/MS quantification of NAD⁺, NADH, NMN, and NAM in tissue homogenates; fluorogenic sirtuin activity assays using acetylated substrate peptides; Western blot for acetylation status of specific sirtuin substrates (acetyl-p53 K382, acetyl-FOXO1 K294, acetyl-PGC-1α); PGC-1α and mitochondrial-biogenesis marker measurement (mtDNA copy number, mitochondrial mass by MitoTracker); and NNMT activity measurement in tissue lysates. Aged-mouse healthspan phenotyping provides in-vivo readout of longevity-relevant sirtuin-NAD⁺ interventions.